Back Bay Life Science Advisors

Happy Thanksgiving from Back Bay Life Science Advisors! 🍁 As we take time to celebrate this season of #gratitude, we’d like to express our heartfelt thanks to our clients, partners, and colleagues who inspire and support us every day. Wishing you and your loved ones a holiday filled with warmth, gratitude, and joy. #HappyThanksgiving #LifeSciences #Innovation #BBLSA

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending November 22nd is now available. Highlights include: ➡️ US indices ended the week with minor gains, largely driven by Nvidia’s strong Q3 earnings ➡️ Licensing deals had one of their busiest weeks in Q4 so far with five deals announced, each with a potential aggregate deal value of $500M or more ⏹️ The largest deal was Kyowa Kirin, Inc.- U.S., paying $330M upfront and pledging up to $933M in milestones to split the US profits of Kura Oncology, Inc.’s Phase 2 oral leukemia treatment, in addition to obtaining commercialization rights for the rest of the world ⏹️ Radiopharmaceuticals continues to be one of the hottest modalities within oncology deals this year as Novartis added another program to its pipeline, penning a research collaboration deal worth up to $745M for the rights of an SSTR2-targeting asset from Ratio Therapeutics ➡️ Novartis made headlines with its $1.1B structured acquisition of Kate Therapeutics, providing the Swiss drug maker with gene therapy preclinical programs targeting Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1) Read the full update here: https://bit.ly/3AX7ob2 #radiopharmaceuticals #oncology #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB 

DNB//Back Bay had an incredible time at BioStock Life Science Summit 2024 in Lund, Sweden! We're proud to support such an engaging and insightful event! A special thank you to Andreas Dirnagl for sharing valuable perspectives on the U.S. election and its implications for the future of healthcare. We’re thrilled to continue our partnership with BioStock - Connecting Innovation and Capital and we're already looking forward to next year’s event! #HealthcareConference #LifeSciences #BBLSA #DNB  

#ICYMI 🔉 Our latest episode of the Back Bay Life Science Report #podcast is live! Join Peter Bak and Christian Thienel as they explore “The Optimism of Bispecific Antibodies” and uncover: ➡️ The biologics of a bispecific antibody and its benefits compared to autologous therapies ➡️ The buzz around Akeso Biopharma and Summit Therapeutics, Inc., PD-1 VEGF bispecific antibody asset ➡️ The broad state of bispecifics in approved products and development pipelines ➡️ The potential of trispecifics, bispecific conjugates and beyond Don’t miss out on this discussion:  https://bit.ly/4enyzcE #Antibodies #Oncology #BBLSA #IndustryInsights #LifeScienceReport #Healthcare #MarketDynamics  

The 15th Annual DNB Nordic Healthcare Conference is just one week away! This event serves as a dynamic platform for investors and companies, driving new investments, partnerships, and networks within the healthcare sector. DNB//Back Bay is excited to welcome the selected companies from the Healthcare Innovation Accelerator (HIA), who will also join us at the Nordic American Healthcare Conference (NAHC) 2025 in New York. At NAHC, these teams will showcase their innovations and connect with potential investors and partners - looking forward to an inspiring gathering of healthcare leaders! Learn more ➡️ https://bit.ly/3CeO4pY  #DNB #BBLSA #HealthcareConference #HealthcareInnovation #NAHC2025 #Leadership #Investing #Networking 

Therapeutic Update: Bispecific Antibodies 🔬 Following this summer's data release from Akeso Biopharma and Summit Therapeutics, Inc. on PD-1/VEGF bispecific antibodies, two notable deals in this space were announced this week, signaling continued momentum and renewed optimism for a vibrant immuno-oncology licensing and M&A market: ➡️ Germany-based BioNTech SE is acquiring Chinese biotech Biotheus Inc. for its PD-1/VEGF bispecific antibody, PM8002 (also known as BNT327). The deal includes an $800M upfront payment and $150M in milestone payments. ➡️ Merck is also moving forward "with speed and rigor" through a licensing agreement with Chinese biotech LaNova Medicines to develop LM-299, with a $588M upfront payment and potential milestones reaching up to $2.7B. Despite the recent buzz within the space, bispecifics are a well-established class of therapeutics. In the latest episode of #BBLSA Report, Peter Bak and Christian Thienel provide an in-depth look at the bispecific landscape, covering major players in hematology, developments in solid tumors, and innovations like bispecific drug conjugates and trispecific technologies. 🎧 Listen to the episode here: https://bit.ly/4enyzcE #IndustryInsights #Healthcare #MarketDynamics #antibodies #oncology 

We’re thrilled to announce the release of our first healthcare analyst #whitepaper with DNB: "Frontiers in CNS Therapeutic Development: Breaching the Blood-Brain Barrier". Authored by #BBLSA’s Peter Bak, Managing Director, and Mavra Nasir, Engagement Manager, alongside Patrik Ling, Senior Analyst Healthcare at DNB Markets, this report provides an in-depth analysis on the complexities of the blood-brain barrier, licensing deals, key enzymes, and cutting-edge technologies that could transform #neurologicaldisorder treatments.  Read the full paper: https://bit.ly/4fpzgnd #BloodBrainBarrier #Neurology #HealthcareInnovation #DNB  

Our partners at DNB are gearing up for the 15th DNB Nordic Healthcare Conference, dedicated to advancing healthcare development across the Nordics. The conference takes place on November 26, 2024, at DNB's head office in Oslo, Norway, and #BBLSA CEO, Jonathan P. Gertler, MD will deliver the keynote address.  Key sessions include:   ➡️ Healthcare Industry Session: Covering healthcare as a potential export industry for Norway, this session will also include the reveal of companies chosen for the Healthcare Innovation Accelerator.  ➡️ Markets Session: Featuring presentations from listed and private Nordic healthcare companies, this portion of the conference offers opportunities for institutional investors to hold one-on-one meetings.  Discover the full agenda and register today here: https://bit.ly/3CeO4pY    

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending November 8th is now available. Highlights include:  ➡️ All three major US indices hit all time-highs on the back of the US presidential election and another rate cut from the Federal Reserve ➡️ Deal making across the capital markets, M&A/licensing, and venture financing had one of its quietest weeks in 2024 YTD, likely due to the US election ➡️ The healthcare sector awaits the impact across the sector of a second Trump term: ⏹ The general sentiment from an M&A perspective has been positive, as some expect to see an increase in activity due to a potentially less hawkish FTC ⏹ Among the sector's many questions is the effect that Robert F. Kennedy Jr. may have on the FDA, CDC and public health overall, as President-elect Trump has promised to let Kennedy “go wild” on health Read the full update here: https://bit.ly/40FyUEt  #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB

The DNB//Back Bay Partnership was delighted to host the healthcare reception with U.S. Ambassador to Sweden, Erik Ramanathan, at #BIOEurope2024.  Together, we welcomed healthcare companies and investors to Stockholm, celebrating the power of US-Nordic collaboration. The evening honored the essential pillars of #lifescience, scientific excellence, strong leadership, committed capital, and the unique bond between our regions—all vital to advancing #healthcareinnovation across borders.  A sincere thank you to everyone who joined us and made this reception truly memorable!  Anne Grabe ♦️ | Peter Behncke | Jonathan P. Gertler, MD | Elisabeth Beskow ♦️   Business Sweden | SwedenBIO | Medicon Valley Alliance | The Life Science Cluster | Oslo Cancer Cluster #DNB #BBLSA